# AliveAndKickn Podcast - Dr Matthias Kloor

Page: https://stenobird.com/podcast/aliveandkick-n-the-podcast-1330226/aliveandkickn-podcast-dr-matthias-kloor
Text version: https://stenobird.com/podcast/aliveandkick-n-the-podcast-1330226/aliveandkickn-podcast-dr-matthias-kloor.md
Podcast: [AliveandKick'n the podcast](https://stenobird.com/podcast/aliveandkick-n-the-podcast-1330226)
Published: 2025-03-17T01:39:12+00:00
Episode link: https://aliveandkickn.libsyn.com/aliveandkickn-podcast-dr-matthias-kloor
Audio file: https://traffic.libsyn.com/secure/aliveandkickn/Dr_Matthias_Kloor.mp3?dest-id=1596059
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/aliveandkick-n-the-podcast-1330226/episodes/aliveandkickn-podcast-dr-matthias-kloor
Duration seconds: 2673

## Resource

I sit down with Dr. Matthias Kloor, Acting Medical Director Applied Tumor Biology at Heidelberg University. We discuss the thought process followed by the hurdles faced in trying to get a Lynch Syndrome vaccine, through the phases, to potentially the proverbial bedside. We discussed collaboration with the NCI in bringing this and other projects to market. We also talk about the European Hereditary Tumor Group, whose conference this year is also in Heidelberg. EHTG is a great group, one that has embraced the advocacy community, similar to CGAIGC and InSIGHT.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/aliveandkick-n-the-podcast-1330226/episodes/aliveandkickn-podcast-dr-matthias-kloor/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/aliveandkick-n-the-podcast-1330226/aliveandkickn-podcast-dr-matthias-kloor.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.